Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating and {REMOVEPT} price target on aTyr Pharma (NASDAQ: ATYR).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE